GPT and hepatocellular carcinoma: A recent interim analysis of the ATTENTION trial [14] suggested that early treatment with tenofovir alafenamide (TAF) reduces the risk of liver-related serious adverse events, including HCC, compared with observation in non-cirrhotic CHB patients with moderate or high viremia but normal or mildly elevated ALT concentrations.